semaglutide patent expiration 2031 2026-2031 Looming GLP-1 drug patent expirations
Description
Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial
M., Keim, N
If your body can't tolerate one GLP-1 drug, you may be able to try another
Forbes SC, et al
The program is voluntary
( 13 Products Available ) Users should verify the drug license and prescription before buying or selling medicines
